Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Polycythemia Vera 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Glioblastoma 1Chromosome 17 deletion 1

Interventions

fludarabine phosphate 20Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 17Busulfan 16ruxolitinib 14Tacrolimus 12Whole-Body Irradiation 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8Cyclosporine 7peginterferon alfa-2a 6Hydroxyurea 6Filgrastim 6Etoposide 6Aspirin 6fludarabine 5Prednisone 5Melphalan 5Imatinib Mesylate 5Cytarabine 5Decitabine 4pomalidomide 3givinostat hydrochloride 3givinostat 3Topotecan 3Thiotepa 3Radiotherapy 3Lenalidomide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Polycythemia Vera × RG7388 × Clear all
NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡